Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1857-1861

  Taiwo, Babafemi ^a   Matining, Roy M ^b   Zheng, Lu ^b   Lederman, Michael M ^c   Rinaldo, Charles R ^d   Kim, Peter S ^e   Berzins, Baiba I ^a   Kuritzkes, Daniel R ^f   Jennings, Amy ^g   Eron, Joseph J ^h   Wilson, Cara C ⁱ  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Microbial translocation; Nucleos(t)ide sparing; Soluble CD14

Indexed keywords

CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; D DIMER; DARUNAVIR PLUS RITONAVIR; GAMMA INTERFERON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; RALTEGRAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

EID: 84880743893     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt120     Document Type: Article

References (12)

1. Taiwo B, Zheng L, Gallien S et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-näive HIV-1-infected patients (ACTG A5262). AIDS 2011; 25: 2113-22.
2. Panel on Antireroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf .
3. Jiao Y, Zhang T, Wang R et al. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol 2012; 25: 333-7.
4. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
5. Sandler NG, Wand H, Roque A et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-90.
6. Kalayjian RC, Machekano RN, Rizk N et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010; 201: 1796-805.
7. Trøseid M, Nowak P, Nyström J et al. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. AIDS 2010; 24: 1733-7.
8. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
9. Cohen Stuart JW, Hazebergh MD, Hamann D et al. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000; 25: 203-11.
10. Robbins GK, Spritzler JG, Chan ES et al. Incomplete reconstitution of T-cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350-61.
11. French MA, King MS, Tschampa JM et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T-cells. J Infect Dis 2009; 200: 1212-5.
12. Lederman MM, Calabrese L, Funderburg NT et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis 2011; 204: 1217-26.